Anti-Mouse CD115 (CSF-1R) - Purified In vivo PLATINUM™ Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

Not available

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

< 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2829355

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this AFS98 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

B
CyTOF®
FA
Depletion

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone AFS98 recognizes an epitope on mouse CD115.

Antigen Distribution

CD115 is expressed on monocytes/macrophages, peritoneal exudate cells, plasmacytoid cells, dendritic cells, and osteoclasts.

Background

CD115 antibody, clone AFS98, recognizes CD115, also known as mouse colony-stimulating factor 1 receptor (CSF-1R and macrophage colony-stimulating factor receptor (M-CSFR). CD115 is a 150kDa single-pass type I membrane protein encoded by the c-fms gene that belongs to the type III protein tyrosine kinase receptor family. CD115 has an immunoglobulin-like extracellular domain, transmembrane domain, and C-terminal tail receptor and is expressed by monocytes, macrophages, plasmacytoid and conventional dendritic cells (DCs), osteoclasts, and their precursors. CD115 is the receptor for CSF1, also known as M-CSF, and IL-34. Binding and signaling through CD115 regulates the proliferation, differentiation, survival, and cytokine-production of monocytes and macrophages^{1, 2}. In addition, CD115 plays a key role in the differentiation and proliferation of osteoclasts as well as their bone resorption activity³. Mutations in CSF-1R are associated with cancer, including myeloid malignancies, Alzheimer’s disease, and other inflammatory and autoimmune diseases⁴. The presence of tumor-associated macrophages (TAMs) expressing CSF-1R correlates with poor survival in various tumor types^{5, 6}, and efforts to eliminate these TAMs using CSF1R small-molecule inhibitors and monoclonal antibodies are currently in clinical trials⁷.

Antigen Details

Protein

CD115

Ligand/Receptor

Macrophage colony stimulating factor (M-CSF), IL-34

PubMed

CD115

NCBI Gene Bank ID

12978

UniProt.org

Information on Uniprot.org

References & Citations

1. Stanley ER., et al. (1982) Cell. 28:71–81
2. Roussel MF., at al. (1988) Cold Spring Harb Symp Quant Biol. 53:521–530
3. Park-Min, KH., et al. (2020) Exp Mol Med 52, 1239–1254
4. Tak, P. P., at al. (2016) Nat. Rev. Drug Disco. 16, 53–70
5. d’Amore F. (2014) Histopathology. 65:490–500
6. Wei YQ., et al. (2012) PLoS One. 7:e50946
7. Rüttinger D., et al. (2017) J Immunother Cancer. 5(1):53

Technical Protocols